AbbVie Enters into a Collaboration to Develop Monoclonal Antibody Therapy for Preventing COVID-19

 AbbVie Enters into a Collaboration to Develop Monoclonal Antibody Therapy for Preventing COVID-19

AbbVie Enters into a Collaboration to Develop Monoclonal Antibody Therapy for Preventing COVID-19

Shots:

  • AbbVie collaborated with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a novel Ab to prevent and treat COVID-19. The collaboration focuses on advancing 47D11, discovered by UU, EMC and HBM that targets the domain of the spike protein of SARS-CoV-2
  • AbbVie will support UU, EMC, and HBM in preclinical activities, while simultaneously preparing late-stage pre/ clinical development. AbbVie to get an option to exclusively license the Ab from the three parties for WW clinical development and commercialization
  • The Ab discovered by UU, EMC, and HBM is based on the mechanism by which it targets the virus and on its developability as a fully human protein. The is designed to facilitate its development and minimize immune-related side effects

Click here to read full press release/ article | Ref: AbbVie | Image: AbbVie

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post